Latest NSCLC Stories
PARIS, May 11, 2015 /PRNewswire/ -- OSE Pharma SA (ISIN: FR0012127173; Mnemo: OSE), a biotechnology company based in France, developing T specific immunotherapy treatments
Protocol Amended to Provide Faster Assessment of Survival Outcomes with Reduced Trial Size BOTHELL, Wash.
- 60 percent of surveyed U.S.
- Data support VAL-083's importance as a potential therapy for non-small cell lung cancer (NSCLC), including drug-resistant NSCLC - VANCOUVER, British Columbia and MENLO PARK, Calif.,
GENEVA, April 17, 2015 /PRNewswire/ -- ASSESS shows plasma circulating tumour DNA (ctDNA) testing for EGFR mutation is a viable alternative
Alexander Chi, MD, a thoracic radiation oncologist at West Virginia University, is the principal investigator in the study of novel treatment approaches for non-small cell lung cancer.
A new study from the RSSearch® Patient Registry, the largest patient registry dedicated to radiosurgery and stereotactic body radiotherapy (SBRT), describes treatment management practices
Study Seeks to Confirm a High Response Rate among Cancer Patients with MET and Axl Genetic Alterations SAN DIEGO, Dec. 23, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc.
Frontier Pharma - NSCLC - Identifying and Commercializing First-in-Class Innovation in Non-Small-Cell Lung Carcinoma provides information on pricing, market analysis, shares, forecast, and company
LUGANO, Switzerland, October 30, 2014 /PRNewswire/ -- In ROMANA 1, a pivotal Phase III study, anamorelin was shown to increase lean body mass and body weight, reduce fatigue
- A woman chauffeur.
- A woman who operates an automobile.